# ALBERT LABS INTERNATIONAL CORP. (formerly ME RESOURCE CORP.)

### **Financial Statements**

Years ended December 31, 2021 and 2020

**Expressed in Canadian Dollars** 

SAM S. MAH INC. CHARTERED PROFESSIONAL ACCOUNTANT UNIT 114B-8988 FRASERTON COURT BURNABY, BC, V5J 5H8 T: 604-617-8858

T: 604-617-8858 F: 604-239-0866

#### INDEPENDENT AUDITOR'S REPORT

To: the Shareholders of

Albert Labs International Corp. (ME Resource Corp.)

#### **Opinion**

I have audited the financial statements of Albert Labs International Corp. (the "Company"), which comprise the statement of financial position as at December 31, 2021 and 2020 and the statement of loss and comprehensive loss, statement of cash flows and statement of changes in shareholders' equity for the year December 31, 2021 and 2020 and notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as at December 31, 2021 and its financial performance and its cash flows for the years then ended in accordance with International Financial Reporting Standards (IFRSs).

#### **Basis for Opinion**

I conducted my audit in accordance with Canadian generally accepted auditing standards. My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Company in accordance with the ethical requirements that are relevant to my audit of the financial statements in Canada, and I have fulfilled my other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

#### **Material Uncertainty Related to Going Concern**

I draw attention to Note 1 in the financial statements, which indicates that the Company incurred a net loss of \$282,073 during the year ended December 31, 2021 and, as of that date, the Company had not yet achieved profitable operations, had accumulated losses of \$9,698,655 since its inception, and expects to incur further losses in the development of its business. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. My opinion is not modified in respect of this matter.

#### **Other Information**

Management is responsible for the other information. The other information comprises the Management Discussion and Analysis.

My opinion on the financial statements does not cover the other information and I do not express any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact. I have nothing to report in this regard.

#### Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. As part of an audit in accordance with Canadian generally accepted auditing standards, I exercise professional judgment and maintain professional skepticism throughout the audit. I also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide those charged with governance with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

The engagement practitioner on the audit resulting in this independent auditor's report is Sam S. Mah, CPA, CA.

"Sam S. Mah Inc."

Chartered Professional Accountant

Burnaby, BC, Canada April 28, 2022

## Albert Labs International Corp. (formerly ME Resource Corp.) Statements of Financial Position

Expressed	in	Canadian	<b>Dollars</b>
-----------	----	----------	----------------

	December 31, 2021	December 31, 2020
	\$	\$
LIABILITIES	*	Ť
Current liabilities		
Accounts payable and accrued liabilities (Note 4)	481,549	382,413
Note payable (Note 5)	-	57,063
Due to related parties (Note 7)	1,610,723	1,370,723
	2,092,272	1,810,199
SHAREHOLDERS' DEFICIENCY		
Share capital (Note 6)	5,861,105	5,861,105
Reserves	1,745,278	1,745,278
Deficit	(9,698,655)	(9,416,582)
	(2,092,272)	(1,810,199)
Total shareholders' deficiency and liabilities	-	-

Note 1: Nature and operation and going concern

Note 10: Subsequent events

Authorized for issuance by the Board of Directors

<u>/s/ Navchand Jagpal</u> <u>/s/Ravinder Kang</u>
<u>Director</u> <u>Director</u>

See accompanying notes to the financial statements

Albert Labs International Corp. (formerly ME Resource Corp.) Statements of Loss and Comprehensive Loss

#### **Expressed in Canadian Dollars**

Years ended December 31,	2021	2020
	\$	\$
Expenses		
Consulting and management (Note 7)	240,000	240,000
Filing fees	21,994	24,241
Interest expense	2,412	82
Office	400	4,260
Professional fees	17,267	15,442
Loss and comprehensive loss	(282,073)	(284,025)
loss per share – basic and diluted	(0.04)	(0.04)
Weighted average number of outstanding		
common shares, basic and diluted	6,367,192	6,367,192

See accompanying notes to the financial statements

\*Post 1:10 share consolidation (Note 10)

#### **Expressed in Canadian Dollars**

Years ended December 31,	2021	2020
	\$	\$
OPERATING ACTIVITIES		
Loss for the year	(282,073)	(284,025)
Items not involve cash		
Accrued consulting fees	240,000	240,000
Accrued interest	-	4,260
Changes in non-cash working capital items:		
- accounts payable and accrued liabilities	99,136	21,944
Cash provided by operating activities	57,063	(17,821)
FINANCING ACTIVITIES		
Repayment of note payable	(57,063)	-
Proceeds from note payable	-	17,821
Cash used in financing activities	(57,063)	17,821
Net cash inflow	-	-
Cash, beginning of year	-	
Cash, end of year	-	-

See accompanying notes to the financial statements

#### Albert Labs International Corp. (formerly ME Resources Corp.) Statements of Changes in Deficiency Expressed in Canadian Dollars

	Share ca	pital	Reserves					
	Number of shares	Amount \$	Stock- option \$	Loan \$	Warrant \$	Deficit \$	Total \$	
Balance, December 31, 2019 (Note 6)	6,367,192	5,861,105	1,694,396	5,121	45,761	(9,132,557)	(1,526,174)	
Loss for the year		-	-	-	-	(284,025)	(284,025)	
Balance, December 31,2020	6,367,192	5,861,105	1,694,396	5,121	45,761	(9,416,582)	(1,810,199)	
Loss for the year	-	-	-	-	-	(282,073)	(282,073)	
Balance, December 31, 2021	6,367,192	5,861,105 -	1,694,396	5,121	45,761	(9,698,655)	(2,092,272)	

See accompanying notes to the financial statements

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

#### 1. NATURE AND CONTINUANCE OF OPERATIONS

ME Resource Corp., ("MEC" or the "Company") was incorporated under the Business Corporation Act (British Columbia) on October 16, 2009. The Company completed a business acquisition during the first quarter of 2022 and changed its name to Albert Labs International Corp.(Note 10). The Company's shares commenced trading on the Canadian Securities Exchange ("CSE") under the symbol ABRT on March 10, 2022. The Company's head office is #201 - 6996 Merritt Avenue, Burnaby, BC V5J 4R6, Canada

These financial statements have been prepared using International Financial Reporting Standards applicable to a going concern, which assume that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. Different bases of measurement may be appropriate if the Company is not expected to continue operations for the foreseeable future. The Company's continuation as a going concern is dependent whether the Company can develop an economically viable business, and generate funds there from and/or raise equity capital to meet current and future obligations. The Company has not yet achieved profitable operations and expects to incur further losses in the development of its business. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs over the next twelve months with loans and/or private placement of common shares. Should the Company be unable to continue as going concern, the net realizable value of its assets may be materially less than the amounts on its statements of financial position.

The recent outbreak of the coronavirus, also known as "COVID-19", has spread across the globe and is impacting worldwide economic activity. Conditions surrounding the coronavirus continue to rapidly evolve and government authorities have implemented emergency measures to mitigate the spread of the virus. The outbreak and the related mitigation measures may have an adverse impact on global economic conditions as well as on the Company's business activities. The extent to which the coronavirus may impact the Company's business activities will depend on future developments, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, business disruptions, and the effectiveness of actions taken in Canada and other countries to contain and treat the disease. These events are highly uncertain and as such, the Company cannot determine their financial impact at this time.

#### 2. BASIC OF PRESENTATION

#### Statement of compliance

These financial statements have been prepared in accordance with the International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and Interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented, unless otherwise stated.

These financial statements were authorized for issue by the Board of Directors on April 28, 2022.

#### **Basis of measurement**

The financial statements have been prepared on an accrual basis and are based on historical costs, except for certain financial instruments which are measured at fair value. The financial statements are presented in Canadian dollars, the functional currency of the Company. The preparation of financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. Estimates and assumptions where there is significant risk of material adjustments to assets and liabilities in future accounting periods include the fair value measurements for measurements for financial instruments and the recognition and measurement of deferred tax assets.

#### 2. BASIS OF PRESENTATION (Continued)

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

#### Significant judgments

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgment in applying the Company's financial statements include:

- the classification of financial instruments;
- the assessment of the Company's ability to continue as a going concern; and
- the determination of the recoverability of the Company's deferred tax assets

#### 3. SIGNIFICANT ACCOUNTING POLICIES

#### Loss per share

The Company presents the basic and diluted loss per share data for its common shares by dividing the loss by the weighted average number of common shares outstanding during the year. For all periods presented, the loss attributable to common shareholders equals the reported loss attributable to owners of the Company. Diluted loss per share is calculated by the treasury stock method. Under the treasury stock method, the weighted average number of common shares outstanding for the calculation of diluted loss per share assumes that the proceeds to be received on the exercise of dilutive share options and warrants are used to repurchase common shares at the average market price during the period.

#### **Financial Instruments**

#### Financial assets

Financial assets are classified and measured based on the business model in which they are held and the characteristics of their contractual cash flows. IFRS 9 contains three categories of financial assets: Measured at amortization cost after initial recognition, at fair value through other comprehensive income ("FVOCI") and at fair value through profit or loss ("FVTPL").

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Equity instruments are generally classified as FVTPL. For equity investment is not held for trading, an entity can make an irrevocable election at initial recognition to measure it at FVOCI with only dividend income recognized in profit or loss.

The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity.

#### Impairment of financial assets

IFRS 9 uses the expected credit loss ("ECL") model. The credit loss model groups receivables based on similar credit risk characteristics and days past due in order to estimate bad debts. The ECL model applies to the Company's receivables.

An 'expected credit loss' impairment model requires a loss allowance to be recognized based on expected credit losses. The estimated present value of future cash flows associated with the asset is determined, and an impairment loss is recognized for the difference between this amount and the carrying amount as follows: the carrying amount of the asset is reduced to estimated present value of the future cash flows associated

#### 3. SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

#### **Financial Instruments (continued)**

Impairment of financial assets (continued)

with the asset, discounted at the financial asset's original effective interest rate, either directly or through the use of an allowance account, and the resulting loss is recognized in profit or loss for the period.

In a subsequent period, if the amount of the impairment loss related to financial assets measured at amortized cost decreases, the previously recognized impairment loss is reversed through profit or loss to the extent that the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortized cost would have been had the impairment not been recognized.

#### Financial liabilities

All financial liabilities are designated as either: (i) FVTPL; or (ii) other financial liabilities. All financial liabilities are classified and subsequently measured at amortized cost except for financial liabilities at FVTPL.

Financial liabilities classified as other financial liabilities are initially recognized at fair value less directly attributable transaction costs. After initial recognition, other financial liabilities are subsequently measured at amortized costs using the effective interest method. The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period. The Company's accounts payable are classified as other financial liabilities.

Financial liabilities classified as FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as FVTPL. Derivatives, including separated embedded derivatives are also classified as held for trading and recognized at fair value with changes in fair value recognized in earnings unless they are designated as effective hedging instruments. Fair value changes on financial liabilities classified as FVTPL are recognized in earnings.

The Company derecognizes a financial liability when its contractual obligations are discharged or canceled, or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and/or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss.

The company's financial assets and liabilities are classified as follow:

IFRS 9 Classification
Amortized cost
Amortized cost
Amortized cost

#### 3. SIGNIFICANT ACCOUNTING POLICIES (Continued)

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

#### **Income taxes**

#### Current income tax:

Current income tax assets and liabilities for the period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date, in the countries where the Company operates and generates taxable income.

Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

#### Deferred tax:

Deferred tax is provided on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

#### 4. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

	December 31, 2021	<b>December 31, 2020</b>
	\$	\$
Trade payables	317,431	343,954
Salaries payable	20,066	20,066
Accrued liabilities	15,695	18,393
Due to Albert Labs (Note 5)	128,357	-
	481,549	382,413

During the year ended December 31, 2021, Albert Labs advanced the Company \$128,357 to finance the Company's operations and for the repayment of certain outstanding payables. This amount owing to the Albert Labs is unsecured, payable on demand, and non-interest bearing (Note 5).

#### 5. NOTE PAYABLE

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

On March 31, 2019, the Company issued an unsecured, note payable to Moonstruck Capital which promises to repay any advances Moonstruck made to cover the Company's expenses. The note carries interest at 10% per annum based on the date of the advances and principal and interest is due on October 31, 2020. The lender further advanced the Company \$17,821 on June 15, 2020, with the same terms of repayment.

The terms of repayment changed to on-demand after October 31, 2020, and subsequently to the year ended December 31, 2020. As of December 31, 2020, the amount of outstanding was \$50,764 with accrued interest of \$6,299, totalling \$57,063.

In March 2021, Albert Labs advanced the Company \$57,433 to fully repay the principal and accrued interest of the above promissory note. The Company recorded an interest expense of \$370 on the note payable to Moonstruck Capital for the year ended December 31, 2021 (Note 4)

#### 6. SHARE CAPITAL

On March 10, 2022, the Company consolidated its common share on 10-1 basis. The presentation of number of outstanding shares, loss per share have been retrospectively amended to reflect this share consolidation.

Authorized share capital: An unlimited number of common shares without par value.

An unlimited number of preferred shares without par value.

Issued and outstanding: 6,367,192 common shares

During the year ended December 31, 2021, the Company did not issue any common shares.

#### **Stock options**

The Company has a stock option plan which provides that the Board of Directors of the Company may grant to directors, officers, employees, and consultants to the Company, non-transferable options to purchase common shares. The number of common shares reserved for issuance will not exceed 10% of the issued and outstanding common shares of the Company. The term of any options granted under the plan may not exceed 5 years. Vesting terms and conditions are established by the Board of Directors.

The Company has not issued stock options during the year ended December 31, 2021. The Company did not have options outstanding as of December 31, 2021, and 2020.

#### Stock option reserve

The stock option reserve records items recognized as stock-based compensation expense and other share-based payments until such time that the stock options or warrants are exercised, at which time the corresponding amount will be transferred to share capital.

#### Warrant reserve

The warrant reserve records the fair value of warrants issued until such time that they are exercised, at which time the corresponding amount will be transferred to share capital.

#### Loan Reserve

Recorded in the loan reserve is a discount on a loan which was issued with interest below market rates.

#### 7. RELATED PARTY TRANSACTIONS

Notes to the Financial Statements

Years Ended December 31, 2021, and 2020

(Expressed in Canadian Dollars)

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers.

#### a) Transactions with key management personnel were as follows:

Years ended December 31,	2021	2020
	\$	\$
Consulting fees charged by a director	60,000	60,000
Consulting fees charged by a company related the CEO	120,000	120,000
Consulting fees charged by the CFO	60,000	60,000
	240,000	240,000

#### b) Balances due to related parties:

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

Due to Related parties	December 31,	December 31,
F	2021	2020
	\$	\$
Directors	424,000	364,000
CFO	379,600	319,600
Companies related to the CEO	807,123	687,123
	1,610,723	1,370,723

#### 8. FINANCIAL INSTRUMENTS

#### **Financial Risk Management**

The Company is exposed in varying degrees to a variety of financial instrument related risks.

#### Credit Risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's exposure to credit risk is minimal.

#### Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash.

Historically, the Company's sources of funding has been the issuance of equity securities/ debt instruments for cash. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

#### Interest Rate Risk

Interest rate risk refers to the risk that fair values of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. The Company does not have material financial assets or liabilities that are exposed to fluctuation of interest rate. As a result, the exposure to interest rate risk is not significant.

#### 8. FINANCIAL INSTRUMENTS (Continued)

Currency Risk

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company does not incur significant expenditures that are denominated in foreign currencies and does not have any commitments that are denominated in foreign currencies. Therefore, the Company's exposure to currency risk is minimal.

#### Capital management

The Company manages its capital structure and make adjustments to it, based on the funds available to the Company. In order to support the acquisition, exploration, and development of exploration and evaluation assets. In the management of capital, the Company includes components of shareholders' equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of management to sustain future development of the business. The business operated by the Company in the development state; as such the company is dependent on external financing to finance its operations.

There were no changes in the Company's approach to capital management during the year. The Company is not subject to any externally imposed capital requirements

#### **Financial instruments**

The Company's financial instruments consist of accounts payable and accrued liabilities, note payable and due to related parties. The fair value of the Company's financial assets and liabilities approximate their carrying amount due to their short terms to maturity.

No transfers occurred between the levels of fair value during the year.

#### Classification of financial instruments

Financial instruments included in the statement of financial position are as follows:

	<b>December 31, 2021</b>	December 31, 2020
	\$	\$
Amortized cost:		
Trade payables	317,431	343,954
Salaries payable	20,066	20,066
Note payable	-	57,063
Due to Albert Labs	128,357	-
Due to related party	1,610,723	1,370,723

#### Fair value

The Company does not have financial instruments that are measured at their fair values. Financial instruments that are not measured at their values are note receivable, trade payables, salaries payable and due to related parties. Their carrying values approximate their fair values due to their short terms to maturity.

#### 9. INCOME TAXES

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

The income tax provisions differ from the expected amounts calculated by applying Canadian combined federal and provincial corporate income tax rates to the Company's loss before income taxes. The components of these differences are as follows:

	2021	2020
Net loss for the year	\$ (282,073)	\$ (284,025)
Statutory tax rate	27%	27%
Income tax recovery at statutory rates	(76,160)	(76,700)
Non-deductible items	-	-
Change in unrecognized deferred tax assets	76,160	76,700
Deferred tax recovery	\$ -	\$ -

The Company's tax-effected deferred tax assets are estimated as follows:

	2021	2020
	\$	\$
Deferred tax assets:		
Non-capital losses carry forward	907,160	831,000
Less: Unrecognized deferred tax assets	(907,160)	(831,000)
Net deferred tax assets	-	-

The Company has approximately \$3,646,000 in non-capital losses available to offset future taxable income. These losses expire between 2029 and 2041.

Tax attributes are subject to review, and potential adjustment by tax authorities.

#### 10. SUBSEQUENT EVENTS

The Company entered into a definitive agreement (the "Transaction") with Albert Labs Inc ("Albert Labs"), a private company in the business of clinical research and drug development, to complete a reverse-take-over arrangement (the "RTO"), whereby the resulting issuer of the RTO intend to secure a listing on the CSE pursuant to approval from the regulatory.

The Transaction was completed on March 10, 2022 and the Company changed its name to Albert Labs International Corp. The shares of the resulting issuer commenced trading on the CSE under the new symbol ABRT on March 10, 2022.

Details of the Transactions are follows:

On March 4, 2022, Albert Labs closed a debt settlement and private placement offering of 19,171,997 Albert Labs' Shares at a price per of \$0.25 per share for gross proceeds of \$4,792,999. The proceeds of the financing will be used for general working capital purposes. The break-down of the private placement offering is as follows:

	Number of Shares	Proceeds
Albert Labs Subscription	10,986,961	\$2,746,740
Albert Labs Debt Settlement(s)	8,185,036	\$2,046,259

#### 10. SUBSEQUENT EVENTS (Continued)

Notes to the Financial Statements Years Ended December 31, 2021, and 2020 (Expressed in Canadian Dollars)

On March 5, 2021, MEC entered into the Share Exchange Agreement with Albert Labs and all of the Albert Labs' Shareholders, which superseded and replaced the Letter Agreement in its entirety. On March 10, 2022 pursuant to the Share Exchange Agreement, MEC acquired an aggregate of 57,835,797 Albert Labs' Common Shares, being all of the issued and outstanding Albert Labs' Shares, in exchange for the issuance of 57,835,797 post-10-1-consolidated common shares of the Company ("Consideration Shares'), subject to the terms and conditions of the Share Exchange Agreement. The fair value of Consideration Shares is \$14,458,949 or \$0.25 per share.

After the completion of the Transaction, the Company also entered into debt settlement agreements with the creditors of MEC to fully settle an aggregate \$1,650,771 in debt/accounts payable (the "**Debt**") with for the issuance of 3,301,542 post-10-1-consolidated common shares (the "**Debt Shares**") at \$0.50 per Debt Share (the "**Debt Settlement**"). All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation

The continuity of the Company's share capital is as follow:

		No of shares	Share capital
2021-12-31	Opening	6,367,192	\$ 5,861,105
2022-03-10	Acquisition of Albert Lab	57,835,797	\$ 14,458,949
2022-03-11	Debt settlement with creditors	3,301,542	\$ 1,650,771
	Ending	67,504,531	\$ 33,752,266